Monopar Q3 net loss $2.4M ($0.19/share); cash $14.3M; Validive interim analysis Q1 2023

Monopar Therapeutics

Net loss of $2.4M ($0.19 per share) vs. $2.5M ($0.20) in Q3 2021; R&D $1.73M, G&A $0.68M.
Cash and equivalents $14.3M; expects to fund VOICE Phase 2b and camsirubicin Ph1b through Nov 2023.
Validive VOICE trial: 73 active sites, >130 patients dosed; Phase 2b enrollment complete; Phase 3 enrollment started.
Blinded interim analysis of Validive Phase 2b data expected to be reported in Q1 2023.
Camsirubicin Ph1b data to be presented at CTOS Nov 16-19; MNPR-202 preclinical data at ASH Dec 10-13.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Monopar Therapeutics reported third quarter ended September 30, 2022 results: net income $2.4 million or $0.19 per share, EPS $0.19 per share.

Period: third quarter ended September 30, 2022
Net income: $2.4 million or $0.19 per share
EPS: $0.19 per share
Result: reported results

Exact text from the filing

Monopar Therapeutics Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Monopar Therapeutics filing history →

Source: SEC EDGAR

accession 0001654954-22-014938

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.